Biotest AG (DE:BIO3)
HAMBURG:BIO3
Top Page
Biotest
(Hamburg:BIO3)
Select Model
Select Model
Rating:62Neutral
Price Target:
€35.00
▲(10.76% Upside)
Action:ReiteratedDate:11/15/25
Biotest's overall stock score of 62 is primarily driven by mixed financial performance (score: 63, weight: 50%), with strengths in cash flow recovery offset by declining profitability and high leverage. Positive technical momentum (score: 75, weight: 30%) supports the score, though valuation concerns (score: 45, weight: 20%) due to a negative P/E ratio highlight risks. The score reflects cautious optimism with notable financial challenges.
Positive Factors
Revenue Model
Biotest's robust revenue model, focusing on essential biopharmaceutical products, ensures consistent demand and stable revenue streams.
Negative Factors
High Leverage
Increased leverage can strain financial stability, limiting Biotest's ability to invest in growth opportunities and increasing vulnerability to economic downturns.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Model
Biotest's robust revenue model, focusing on essential biopharmaceutical products, ensures consistent demand and stable revenue streams.
Read all positive factors
Biotest (BIO3) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€1.45B
Dividend Yield0.13%
Average Volume (3M)729.00
Price to Earnings (P/E)―
Beta (1Y)0.03
Revenue Growth-18.82%
EPS Growth-113.85%
CountryDE
Employees2,495
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,785,727
10 Day Avg. Volume974
30 Day Avg. Volume729
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biotest Business Overview & Revenue Model
Company Description
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunolog...
How the Company Makes Money
Biotest generates revenue primarily through the sale of its plasma-derived products, which are marketed to hospitals, clinics, and healthcare providers worldwide. The company operates a revenue model based on direct sales and distribution partners...
Biotest Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
55
Neutral
Cash Flow
70
Positive
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 726.20M | 684.60M | 516.10M | 515.60M | 484.20M |
| Gross Profit | 223.80M | 280.30M | 124.90M | 80.70M | 130.10M |
| EBITDA | 120.40M | 179.00M | 28.30M | -17.70M | 16.00M |
| Net Income | 26.40M | 127.00M | -31.60M | -63.30M | -31.40M |
Balance Sheet | |||||
| Total Assets | 1.43B | 1.41B | 1.20B | 1.10B | 1.13B |
| Cash, Cash Equivalents and Short-Term Investments | 119.50M | 118.50M | 136.60M | 117.50M | 89.20M |
| Total Debt | 597.20M | 689.80M | 574.30M | 496.30M | 469.10M |
| Total Liabilities | 903.30M | 912.00M | 831.90M | 723.80M | 689.70M |
| Stockholders Equity | 530.70M | 498.90M | 371.10M | 380.40M | 441.60M |
Cash Flow | |||||
| Free Cash Flow | 32.20M | -36.10M | -69.80M | 15.70M | -43.70M |
| Operating Cash Flow | 60.90M | -2.70M | -40.50M | 33.90M | -16.70M |
| Investing Cash Flow | -25.70M | 1.30M | -37.00M | -23.40M | -14.60M |
| Financing Cash Flow | -35.40M | -6.80M | 89.60M | 22.60M | 42.00M |
Biotest Technical Analysis
Positive
31.60
Price Trends
31.85
Positive
31.62
Positive
30.64
Positive
Market Momentum
0.09
Negative
52.83
Neutral
44.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BIO3, the sentiment is Positive. The current price of 31.6 is below the 20-day moving average (MA) of 31.94, below the 50-day MA of 31.85, and above the 200-day MA of 30.64, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 52.83 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:BIO3.
Biotest Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | €1.45B | -51.69 | 4.98% | 0.13% | -18.82% | -113.85% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | €332.96M | -2.28 | -39.02% | ― | -14.84% | -338.52% | |
46 Neutral | €52.43M | -4.72 | -337.77% | ― | -4.90% | -69.80% | |
42 Neutral | €130.53M | -3.18 | -391.55% | ― | -64.15% | -39.31% |
* General Sector Average
DE:BIO3
Biotest
32.00
2.04
6.82%
DE:BNN
B.R.A.I.N. Biotechnology Research and Information Network
2.40
0.18
8.11%
DE:CNW
co.don AG
0.02
<0.01
25.00%
DE:MDG1
Medigene
0.03
-0.18
-87.75%
DE:HPHA
Heidelberg Pharma AG
2.79
0.16
6.08%
DE:FYB
Formycon AG
18.84
-1.56
-7.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.